Key statistics
On Thursday, HUTCHMED (China) Ltd (HCM:NSQ) closed at 17.68, -19.34% below its 52-week high of 21.92, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.81 |
---|---|
High | 17.82 |
Low | 17.52 |
Bid | 17.25 |
Offer | 18.14 |
Previous close | 17.96 |
Average volume | 75.46k |
---|---|
Shares outstanding | 174.31m |
Free float | 88.72m |
P/E (TTM) | -- |
Market cap | 3.14bn USD |
EPS (TTM) | -0.2497 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Appointment of Independent Non-executive Director
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
- Clinical Data to be Presented at ASH and ESMO Asia
- HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
- First Commercial Milestone Payment
- Total Voting Rights
- HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
- Vesting of awards under the LTIP
- SAVANNAH: clinically meaningful response rate
- HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
More ▼